PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China

Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) in China; however, the prognostic factors associated with effects in these patients are still controversial. In this study, we retrospectively reviewed the data fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kai-Jie, Pei, Xin-Qi, Tian, Ge, Wu, Da-Peng, Fan, Jin-Hai, Jiang, Yu-Mei, He, Da-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858103/
https://www.ncbi.nlm.nih.gov/pubmed/28905815
http://dx.doi.org/10.4103/aja.aja_34_17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858103/
https://www.ncbi.nlm.nih.gov/pubmed/28905815
http://dx.doi.org/10.4103/aja.aja_34_17

Ejemplares similares